Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919).
W. Parulekar
No relevant relationships to disclose
J. W. Chapman
No relevant relationships to disclose
S. Aparicio
No relevant relationships to disclose
Y. Murray
No relevant relationships to disclose
F. M. Boyle
No relevant relationships to disclose
A. Di Leo
Consultant or Advisory Role - GlaxoSmithKline; Roche; Sanofi
Honoraria - GlaxoSmithKline; Roche; Sanofi
Research Funding - GlaxoSmithKline
B. Kaufman
No relevant relationships to disclose
C. Levy
No relevant relationships to disclose
A. Manikhas
No relevant relationships to disclose
M. Martin
No relevant relationships to disclose
K. I. Pritchard
Consultant or Advisory Role - Abraxis BioScience (U); Boehringer Ingelheim (U); Novartis; Pfizer (U); Roche (U)
Honoraria - Abraxis BioScience; Boehringer Ingelheim; Novartis; Pfizer; Roche
Expert Testimony - AstraZeneca (U); Novartis (U)
L. S. Schwartzberg
No relevant relationships to disclose
M. J. Burnell
No relevant relationships to disclose
S. Dent
No relevant relationships to disclose
S. Ellard
No relevant relationships to disclose
K. S. Tonkin
No relevant relationships to disclose
T. J. Whelan
No relevant relationships to disclose
J. Lemieux
No relevant relationships to disclose
L. Bordeleau
No relevant relationships to disclose
K. A. Gelmon
No relevant relationships to disclose